查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1442894

蛋白質治療市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10個工作天內

價格

蛋白質治療市場 - 報告範圍

TMR 關於全球蛋白質治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球蛋白質治療市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球蛋白質治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解蛋白質治療市場。

該報告深入研究了全球蛋白質治療市場的競爭格局。全球蛋白質治療市場的主要參與者已經確定，並且每位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球蛋白質治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測
  • 波特五力分析

第 5 章：關鍵見解

  • 歐盟或美國已批准或正在審查的治療性單株抗體。
  • 監管場景
  • 重點產品或品牌分析
  • 技術進步。
  • 透過結構和化學設計工程基於蛋白質的療法

第 6 章：全球市場分析與預測：依產品分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按產品，2017-2031
    • 單株抗體
    • 酵素替代療法
    • 細胞因子
      • 干擾素
      • 白血球介素
      • 生長因子
    • 融合蛋白
    • 抗凝血劑
    • 骨形態發生蛋白 (BMP)
    • 荷爾蒙
    • 其他（工程蛋白質支架等）
  • 市場吸引力分析：按產品

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2017-2031
    • 代謝紊亂
    • 免疫系統疾病
    • 血液系統疾病
    • 癌症
    • 遺傳性疾病
  • 市場吸引力分析：按應用

第 8 章：全球市場分析與預測：按管理途徑

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2017-2031
    • 注射蛋白
    • 口服蛋白質
  • 市場吸引力分析：按給藥途徑

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 公司市佔率分析 (2022)
  • 公司簡介
    • Thermo Fisher Scientific, Inc.
    • Genzyme Corporation (Sanofi)
    • AbbVie, Inc.
    • Sanofi
    • Leadiant Biosciences
    • Takeda Pharmaceutical Company Limited
    • Amicus Therapeutics
    • Bayer AG
    • Bristol-Myers Squibb
    • DAIICHI SANKYO COMPANY
    • Abbott
    • Sanofi
Product Code: TMRGL2035

Protein Therapeutics Market - Scope of Report

TMR's report on the global protein therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global protein therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global protein therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the protein therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global protein therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global protein therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global protein therapeutics market.

The report delves into the competitive landscape of the global protein therapeutics market. Key players operating in the global protein therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global protein therapeutics market profiled in this report.

Key Questions Answered in Global protein therapeutics Market Report:

  • What is the sales/revenue generated by protein therapeutics across all regions during the forecast period?
  • What are the opportunities in the global protein therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Protein Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global protein therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global protein therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global protein therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Protein Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.
  • 5.2. Regulatory Scenario
  • 5.3. Key Products or Brand Analysis
  • 5.4. Technological Advances in Protein Therapeutics.
  • 5.5. Engineering protein-based therapeutics through structural and chemical design

6. Global Protein Therapeutics Market Analysis and Forecast, By Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Product, 2017-2031
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Enzyme Replacement Therapy
    • 6.3.3. Cytokines
      • 6.3.3.1. Interferons
      • 6.3.3.2. Interleukins
      • 6.3.3.3. Growth Factors
    • 6.3.4. Fusion Proteins
    • 6.3.5. Anti-coagulants
    • 6.3.6. Bone Morphogenetic Proteins (BMPs)
    • 6.3.7. Hormones
    • 6.3.8. Others (engineered protein scaffolds, etc.)
  • 6.4. Market Attractiveness Analysis, By Product

7. Global Protein Therapeutics Market Analysis and Forecast, By Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Metabolic Disorders
    • 7.3.2. Immunologic Disorders
    • 7.3.3. Hematological Disorders
    • 7.3.4. Cancer
    • 7.3.5. Genetic Disorders
  • 7.4. Market Attractiveness Analysis, By Application

8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Injectable Proteins
    • 8.3.2. Oral Proteins
  • 8.4. Market Attractiveness Analysis, By Route of Administration

9. Global Protein Therapeutics Market Analysis and Forecast, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, By Region

10. North America Protein Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2017-2031
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Enzyme Replacement Therapy
    • 10.2.3. Cytokines
      • 10.2.3.1. Interferons
      • 10.2.3.2. Interleukins
      • 10.2.3.3. Growth Factors
    • 10.2.4. Fusion Proteins
    • 10.2.5. Anti-coagulants
    • 10.2.6. Bone Morphogenetic Proteins (BMPs)
    • 10.2.7. Hormones
    • 10.2.8. Others (engineered protein scaffolds, etc.)
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Metabolic Disorders
    • 10.3.2. Immunologic Disorders
    • 10.3.3. Hematological Disorders
    • 10.3.4. Cancer
    • 10.3.5. Genetic Disorders
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Injectable Proteins
    • 10.4.2. Oral Proteins
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Application
    • 10.6.3. By Route of Administration
    • 10.6.4. By Country

11. Europe Protein Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Monoclonal Antibodies
    • 11.2.2. Enzyme Replacement Therapy
    • 11.2.3. Cytokines
      • 11.2.3.1. Interferons
      • 11.2.3.2. Interleukins
      • 11.2.3.3. Growth Factors
    • 11.2.4. Fusion Proteins
    • 11.2.5. Anti-coagulants
    • 11.2.6. Bone Morphogenetic Proteins (BMPs)
    • 11.2.7. Hormones
    • 11.2.8. Others (engineered protein scaffolds, etc.)
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Metabolic Disorders
    • 11.3.2. Immunologic Disorders
    • 11.3.3. Hematological Disorders
    • 11.3.4. Cancer
    • 11.3.5. Genetic Disorders
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Injectable Proteins
    • 11.4.2. Oral Proteins
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Application
    • 11.6.3. By Route of Administration
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Protein Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Enzyme Replacement Therapy
    • 12.2.3. Cytokines
      • 12.2.3.1. Interferons
      • 12.2.3.2. Interleukins
      • 12.2.3.3. Growth Factors
    • 12.2.4. Fusion Proteins
    • 12.2.5. Anti-coagulants
    • 12.2.6. Bone Morphogenetic Proteins (BMPs)
    • 12.2.7. Hormones
    • 12.2.8. Others (engineered protein scaffolds, etc.)
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Metabolic Disorders
    • 12.3.2. Immunologic Disorders
    • 12.3.3. Hematological Disorders
    • 12.3.4. Cancer
    • 12.3.5. Genetic Disorders
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Injectable Proteins
    • 12.4.2. Oral Proteins
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Product
    • 12.6.2. By Application
    • 12.6.3. By Route of Administration
    • 12.6.4. By Country/Sub-region

13. Latin America Protein Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Monoclonal Antibodies
    • 13.2.2. Enzyme Replacement Therapy
    • 13.2.3. Cytokines
      • 13.2.3.1. Interferons
      • 13.2.3.2. Interleukins
      • 13.2.3.3. Growth Factors
    • 13.2.4. Fusion Proteins
    • 13.2.5. Anti-coagulants
    • 13.2.6. Bone Morphogenetic Proteins (BMPs)
    • 13.2.7. Hormones
    • 13.2.8. Others (engineered protein scaffolds, etc.)
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Metabolic Disorders
    • 13.3.2. Immunologic Disorders
    • 13.3.3. Hematological Disorders
    • 13.3.4. Cancer
    • 13.3.5. Genetic Disorders
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Injectable Proteins
    • 13.4.2. Oral Proteins
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Product
    • 13.6.2. By Application
    • 13.6.3. By Route of Administration
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Monoclonal Antibodies
    • 14.2.2. Enzyme Replacement Therapy
    • 14.2.3. Cytokines
      • 14.2.3.1. Interferons
      • 14.2.3.2. Interleukins
      • 14.2.3.3. Growth Factors
    • 14.2.4. Fusion Proteins
    • 14.2.5. Anti-coagulants
    • 14.2.6. Bone Morphogenetic Proteins (BMPs)
    • 14.2.7. Hormones
    • 14.2.8. Others (engineered protein scaffolds, etc.)
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Metabolic Disorders
    • 14.3.2. Immunologic Disorders
    • 14.3.3. Hematological Disorders
    • 14.3.4. Cancer
    • 14.3.5. Genetic Disorders
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Injectable Proteins
    • 14.4.2. Oral Proteins
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Product
    • 14.6.2. By Application
    • 14.6.3. By Route of Administration
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Thermo Fisher Scientific, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Material Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Genzyme Corporation (Sanofi)
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Material Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AbbVie, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Material Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sanofi
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Material Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Leadiant Biosciences
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Material Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Takeda Pharmaceutical Company Limited
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Material Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Amicus Therapeutics
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Material Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bayer AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Material Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Bristol-Myers Squibb
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Material Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. DAIICHI SANKYO COMPANY
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Material Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Abbott
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Material Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Sanofi
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Material Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 02: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 03: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 06: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 07: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 11: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 14: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 15: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 19: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 22: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 23: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Protein Therapeutics Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Protein Therapeutics Market Value Share, by Product (2022)
  • Figure 03: Global Protein Therapeutics Market Value Share, by Application (2022)
  • Figure 04: Global Protein Therapeutics Market Value Share, by End-user (2022)
  • Figure 05: Global Protein Therapeutics Market Value Share, by Region (2022)
  • Figure 06: Global Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 07: Global Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 08: Global Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 09: Global Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 10: Global Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 11: Global Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 12: Global Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 13: Global Protein Therapeutics Market Value Share, by Region, 2017-2031
  • Figure 14: Global Protein Therapeutics Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 15: North America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 16: North America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 17: North America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 18: North America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 19: North America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 20: North America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 21: North America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 22: North America Protein Therapeutics Market Value Share, by Country, 2017-2031
  • Figure 23: North America Protein Therapeutics Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 24: Europe Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 25: Europe Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 26 : Europe Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 27: Europe Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 28: Europe Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 29: Europe Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 30: Europe Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 31: Europe Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 32: Europe Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 33: Asia Pacific Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 34: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 35: Asia Pacific Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 36: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 37: Asia Pacific Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 38: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 39: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 40 : Asia Pacific Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 41: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 42: Latin America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 43: Latin America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 44: Latin America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 45: Latin America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 46: Latin America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 47: Latin America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 48: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 45: Latin America Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 50: Latin America Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 51: Middle East & Africa Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 52: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 53: Middle East & Africa Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 54: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 55: Middle East & Africa Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 56: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 57: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 58: Middle East & Africa Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 59: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031